Attention-deficit / hyperactivity disorder (ADHD) is a common childhood disorder that can persist into adulthood, although diagnosis and treatment initiation can occur at any age. Diagnosis and drug treatment among adults has historically lagged behind that of pediatric patients, but growing awareness of ADHD as an adult disorder—influenced in part by updated diagnostic criteria—has in recent years fueled greater industry focus on adult patients. While not all psychostimulants are approved specifically for use in adult ADHD, they are central to treating these patients, capturing the majority of U.S. patient and market share; in particular, amphetamines see greater use in adults than in the pediatric population. At the same time, nonstimulants remain key therapeutic alternatives for this population. This study uses national patient-level claims data to examine prescribing patterns of psychostimulants and nonstimulants in adult patients with ADHD to explore the distinct treatment dynamics of this market.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Geographies: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Atomoxetine, guanfacine ER, methylphenidate CR, mixed amphetamine salts ER, Mydayis, Vyvanse
Key analysis provided: